Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-04-28

AUTHORS

Luciano Scopece, Enrico Franceschi, Giovanna Cavallo, Anna Paioli, Gabriele Paioli, Rosa Conforti, Emanuela Palmerini, Carlotta Berzioli, Federica Spagnolli, Roberta Degli Esposti, Lucio Crinò

ABSTRACT

BackgroundOligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting.MethodsIn this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1–3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors.ResultsThirty-two patients were enrolled. Median age was 42 years (range 22–66); median ECOG PS was 0 (range 0–2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression–free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3–4 neutropenia in 5 (15.6%) patients.ConclusionsIn this trial CE regimen has shown relevant activity with a favourable safety profile. More... »

PAGES

299-305

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y

DOI

http://dx.doi.org/10.1007/s11060-006-9144-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021423420

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16645720


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carboplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etoposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Loss of Heterozygosity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scopece", 
        "givenName": "Luciano", 
        "id": "sg:person.0633145402.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633145402.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Franceschi", 
        "givenName": "Enrico", 
        "id": "sg:person.01073030767.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073030767.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cavallo", 
        "givenName": "Giovanna", 
        "id": "sg:person.01005014460.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005014460.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paioli", 
        "givenName": "Anna", 
        "id": "sg:person.01235471460.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paioli", 
        "givenName": "Gabriele", 
        "id": "sg:person.01167356260.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167356260.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Conforti", 
        "givenName": "Rosa", 
        "id": "sg:person.0675350014.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675350014.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmerini", 
        "givenName": "Emanuela", 
        "id": "sg:person.01210215667.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berzioli", 
        "givenName": "Carlotta", 
        "id": "sg:person.01122560745.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122560745.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spagnolli", 
        "givenName": "Federica", 
        "id": "sg:person.0756115375.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756115375.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Esposti", 
        "givenName": "Roberta Degli", 
        "id": "sg:person.0740317466.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740317466.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414405.0", 
          "name": [
            "Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crin\u00f2", 
        "givenName": "Lucio", 
        "id": "sg:person.01306124223.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306124223.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00177478", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040898461", 
          "https://doi.org/10.1007/bf00177478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008198089", 
          "https://doi.org/10.1038/sj.bjc.6602105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023147688", 
          "https://doi.org/10.1007/bf00686001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02390176", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047077907", 
          "https://doi.org/10.1007/bf02390176"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-04-28", 
    "datePublishedReg": "2006-04-28", 
    "description": "BackgroundOligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting.MethodsIn this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120\u00a0mg/m2 on days 1\u20133 every 28\u00a0days) in patients with recurrent/progressive oligodendroglial tumors.ResultsThirty-two patients were enrolled. Median age was 42\u00a0years (range 22\u201366); median ECOG PS was 0 (range 0\u20132); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8\u00a0months, progression\u2013free survivals at 6 and 12\u00a0months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3\u20134 neutropenia in 5 (15.6%) patients.ConclusionsIn this trial CE regimen has shown relevant activity with a favourable safety profile.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11060-006-9144-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "79"
      }
    ], 
    "keywords": [
      "CE regimen", 
      "response rate", 
      "oligodendroglial tumors", 
      "current chemotherapy regimens", 
      "median ECOG PS", 
      "progression-free survival", 
      "phase II trial", 
      "ResultsThirty-two patients", 
      "favorable safety profile", 
      "chemosensitive disease", 
      "ECOG PS", 
      "stable disease", 
      "chemotherapy regimens", 
      "etoposide regimen", 
      "II trial", 
      "median age", 
      "complete response", 
      "partial response", 
      "median time", 
      "active treatment", 
      "safety profile", 
      "anaplastic oligoastrocytoma", 
      "grade 3", 
      "toxicity profile", 
      "patients", 
      "regimen", 
      "tumors", 
      "carboplatin", 
      "oligoastrocytomas", 
      "disease", 
      "months", 
      "neutropenia", 
      "regimens", 
      "chemotherapy", 
      "MethodsIn", 
      "recurrent", 
      "trials", 
      "progression", 
      "response", 
      "efficacy", 
      "survival", 
      "age", 
      "treatment", 
      "ConclusionsIn", 
      "toxicity", 
      "overall results", 
      "rate", 
      "profile", 
      "relevant activities", 
      "years", 
      "setting", 
      "activity", 
      "time", 
      "results", 
      "PS"
    ], 
    "name": "Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors", 
    "pagination": "299-305", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021423420"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-006-9144-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16645720"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-006-9144-y", 
      "https://app.dimensions.ai/details/publication/pub.1021423420"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_427.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11060-006-9144-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-006-9144-y'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      21 PREDICATES      100 URIs      88 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-006-9144-y schema:about N0d5a598c1a8c4f2298082eb30d0be9f6
2 N1e5d5455294343d4840f5dd9d709ca28
3 N2589d1e763e9402799adedbca5eb8783
4 N2acebbeee0764f63ae1cc4153d570a2f
5 N30cdfbb868c6474da2f296e09a106d00
6 N330e97dfae364ad4b2fdc3409cbf2d01
7 N3a8e3535b1524cad93dbf3cfa532add0
8 N4d46eec8a4804439bf136a873efda2c2
9 N632bce40182e4de5b904ab3336e12966
10 N8695a10dffa248b3bb6c425a9a568a3d
11 Na2d78ccf8ed04d1db11808b3b52dbf0e
12 Naf4ec07eb0ed435d9533d0c2d6f12afa
13 Nbc2aee3983904012b440c1a396604eaa
14 Ncd6e6559e5e74845abb5b91140915c25
15 Ncee009925a3746e3be5d319671306af3
16 Ndb28074745c049fdb19496ac07738820
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N4806e71c234e42b2b134037662d159c7
20 schema:citation sg:pub.10.1007/bf00177478
21 sg:pub.10.1007/bf00686001
22 sg:pub.10.1007/bf02390176
23 sg:pub.10.1038/sj.bjc.6602105
24 schema:datePublished 2006-04-28
25 schema:datePublishedReg 2006-04-28
26 schema:description BackgroundOligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting.MethodsIn this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1–3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors.ResultsThirty-two patients were enrolled. Median age was 42 years (range 22–66); median ECOG PS was 0 (range 0–2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression–free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3–4 neutropenia in 5 (15.6%) patients.ConclusionsIn this trial CE regimen has shown relevant activity with a favourable safety profile.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf N20190dd9d5c74ebb9115019ffb6637f4
30 N51015e031fe64a239bbfdc3a3f1302df
31 sg:journal.1094205
32 schema:keywords CE regimen
33 ConclusionsIn
34 ECOG PS
35 II trial
36 MethodsIn
37 PS
38 ResultsThirty-two patients
39 active treatment
40 activity
41 age
42 anaplastic oligoastrocytoma
43 carboplatin
44 chemosensitive disease
45 chemotherapy
46 chemotherapy regimens
47 complete response
48 current chemotherapy regimens
49 disease
50 efficacy
51 etoposide regimen
52 favorable safety profile
53 grade 3
54 median ECOG PS
55 median age
56 median time
57 months
58 neutropenia
59 oligoastrocytomas
60 oligodendroglial tumors
61 overall results
62 partial response
63 patients
64 phase II trial
65 profile
66 progression
67 progression-free survival
68 rate
69 recurrent
70 regimen
71 regimens
72 relevant activities
73 response
74 response rate
75 results
76 safety profile
77 setting
78 stable disease
79 survival
80 time
81 toxicity
82 toxicity profile
83 treatment
84 trials
85 tumors
86 years
87 schema:name Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors
88 schema:pagination 299-305
89 schema:productId N444542a7db7f4349bb0191c00a978c38
90 N532a1eec04684052910d0814f8dd4e15
91 N9b3989aefb88430a9b475ad9af7b1e0d
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021423420
93 https://doi.org/10.1007/s11060-006-9144-y
94 schema:sdDatePublished 2022-11-24T20:52
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Nd15c775a0d9a47ef86359380fd500ed8
97 schema:url https://doi.org/10.1007/s11060-006-9144-y
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N0d5a598c1a8c4f2298082eb30d0be9f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Neoplasm Recurrence, Local
103 rdf:type schema:DefinedTerm
104 N11ff0023287d451080adfeba747131cd rdf:first sg:person.0675350014.28
105 rdf:rest Nd64ce1448d284f10a33c54c67c3ea258
106 N12eca0ee892146d5b15186294d426251 rdf:first sg:person.01005014460.46
107 rdf:rest Na41255aa2bd348498efbfe8820e3a663
108 N1d056da5cb144da88d25aa8fcb72dc8d rdf:first sg:person.01073030767.87
109 rdf:rest N12eca0ee892146d5b15186294d426251
110 N1e5d5455294343d4840f5dd9d709ca28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Survival Analysis
112 rdf:type schema:DefinedTerm
113 N20190dd9d5c74ebb9115019ffb6637f4 schema:issueNumber 3
114 rdf:type schema:PublicationIssue
115 N2589d1e763e9402799adedbca5eb8783 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Antineoplastic Combined Chemotherapy Protocols
117 rdf:type schema:DefinedTerm
118 N26bc208cd8c04919ad23fefae8cfe7d4 rdf:first sg:person.0756115375.62
119 rdf:rest N916c52b382654aa5b6b492eb7a719354
120 N2acebbeee0764f63ae1cc4153d570a2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Etoposide
122 rdf:type schema:DefinedTerm
123 N30cdfbb868c6474da2f296e09a106d00 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Female
125 rdf:type schema:DefinedTerm
126 N330e97dfae364ad4b2fdc3409cbf2d01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Adult
128 rdf:type schema:DefinedTerm
129 N3a8e3535b1524cad93dbf3cfa532add0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Glioma
131 rdf:type schema:DefinedTerm
132 N444542a7db7f4349bb0191c00a978c38 schema:name dimensions_id
133 schema:value pub.1021423420
134 rdf:type schema:PropertyValue
135 N4806e71c234e42b2b134037662d159c7 rdf:first sg:person.0633145402.85
136 rdf:rest N1d056da5cb144da88d25aa8fcb72dc8d
137 N4d46eec8a4804439bf136a873efda2c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Middle Aged
139 rdf:type schema:DefinedTerm
140 N51015e031fe64a239bbfdc3a3f1302df schema:volumeNumber 79
141 rdf:type schema:PublicationVolume
142 N532a1eec04684052910d0814f8dd4e15 schema:name pubmed_id
143 schema:value 16645720
144 rdf:type schema:PropertyValue
145 N632bce40182e4de5b904ab3336e12966 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Loss of Heterozygosity
147 rdf:type schema:DefinedTerm
148 N67fa37c564e24082b84ce537c0c11049 rdf:first sg:person.01306124223.21
149 rdf:rest rdf:nil
150 N6aeffb703657413389437e3469041eee rdf:first sg:person.01167356260.55
151 rdf:rest N11ff0023287d451080adfeba747131cd
152 N8695a10dffa248b3bb6c425a9a568a3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Carboplatin
154 rdf:type schema:DefinedTerm
155 N916c52b382654aa5b6b492eb7a719354 rdf:first sg:person.0740317466.20
156 rdf:rest N67fa37c564e24082b84ce537c0c11049
157 N9b3989aefb88430a9b475ad9af7b1e0d schema:name doi
158 schema:value 10.1007/s11060-006-9144-y
159 rdf:type schema:PropertyValue
160 Na2d78ccf8ed04d1db11808b3b52dbf0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Treatment Outcome
162 rdf:type schema:DefinedTerm
163 Na41255aa2bd348498efbfe8820e3a663 rdf:first sg:person.01235471460.73
164 rdf:rest N6aeffb703657413389437e3469041eee
165 Nae81568a76914d16b9a4502f6d1854d6 rdf:first sg:person.01122560745.27
166 rdf:rest N26bc208cd8c04919ad23fefae8cfe7d4
167 Naf4ec07eb0ed435d9533d0c2d6f12afa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Aged
169 rdf:type schema:DefinedTerm
170 Nbc2aee3983904012b440c1a396604eaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Disease-Free Survival
172 rdf:type schema:DefinedTerm
173 Ncd6e6559e5e74845abb5b91140915c25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Male
175 rdf:type schema:DefinedTerm
176 Ncee009925a3746e3be5d319671306af3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Humans
178 rdf:type schema:DefinedTerm
179 Nd15c775a0d9a47ef86359380fd500ed8 schema:name Springer Nature - SN SciGraph project
180 rdf:type schema:Organization
181 Nd64ce1448d284f10a33c54c67c3ea258 rdf:first sg:person.01210215667.35
182 rdf:rest Nae81568a76914d16b9a4502f6d1854d6
183 Ndb28074745c049fdb19496ac07738820 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Brain Neoplasms
185 rdf:type schema:DefinedTerm
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
190 schema:name Clinical Sciences
191 rdf:type schema:DefinedTerm
192 sg:journal.1094205 schema:issn 0167-594X
193 1573-7373
194 schema:name Journal of Neuro-Oncology
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01005014460.46 schema:affiliation grid-institutes:grid.414405.0
198 schema:familyName Cavallo
199 schema:givenName Giovanna
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005014460.46
201 rdf:type schema:Person
202 sg:person.01073030767.87 schema:affiliation grid-institutes:grid.414405.0
203 schema:familyName Franceschi
204 schema:givenName Enrico
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073030767.87
206 rdf:type schema:Person
207 sg:person.01122560745.27 schema:affiliation grid-institutes:grid.414405.0
208 schema:familyName Berzioli
209 schema:givenName Carlotta
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122560745.27
211 rdf:type schema:Person
212 sg:person.01167356260.55 schema:affiliation grid-institutes:grid.414405.0
213 schema:familyName Paioli
214 schema:givenName Gabriele
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167356260.55
216 rdf:type schema:Person
217 sg:person.01210215667.35 schema:affiliation grid-institutes:grid.414405.0
218 schema:familyName Palmerini
219 schema:givenName Emanuela
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35
221 rdf:type schema:Person
222 sg:person.01235471460.73 schema:affiliation grid-institutes:grid.414405.0
223 schema:familyName Paioli
224 schema:givenName Anna
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73
226 rdf:type schema:Person
227 sg:person.01306124223.21 schema:affiliation grid-institutes:grid.414405.0
228 schema:familyName Crinò
229 schema:givenName Lucio
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306124223.21
231 rdf:type schema:Person
232 sg:person.0633145402.85 schema:affiliation grid-institutes:grid.414405.0
233 schema:familyName Scopece
234 schema:givenName Luciano
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633145402.85
236 rdf:type schema:Person
237 sg:person.0675350014.28 schema:affiliation grid-institutes:grid.414405.0
238 schema:familyName Conforti
239 schema:givenName Rosa
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675350014.28
241 rdf:type schema:Person
242 sg:person.0740317466.20 schema:affiliation grid-institutes:grid.414405.0
243 schema:familyName Esposti
244 schema:givenName Roberta Degli
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740317466.20
246 rdf:type schema:Person
247 sg:person.0756115375.62 schema:affiliation grid-institutes:grid.414405.0
248 schema:familyName Spagnolli
249 schema:givenName Federica
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756115375.62
251 rdf:type schema:Person
252 sg:pub.10.1007/bf00177478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040898461
253 https://doi.org/10.1007/bf00177478
254 rdf:type schema:CreativeWork
255 sg:pub.10.1007/bf00686001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023147688
256 https://doi.org/10.1007/bf00686001
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/bf02390176 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047077907
259 https://doi.org/10.1007/bf02390176
260 rdf:type schema:CreativeWork
261 sg:pub.10.1038/sj.bjc.6602105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008198089
262 https://doi.org/10.1038/sj.bjc.6602105
263 rdf:type schema:CreativeWork
264 grid-institutes:grid.414405.0 schema:alternateName Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy
265 schema:name Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...